DIFLUNISAL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Diflunisal, and what generic alternatives are available?
Diflunisal is a drug marketed by Ani Pharms, Dastech Intl, Heritage Pharma, Purepac Pharm, Teva, Watson Labs, and Zydus Pharms. and is included in nine NDAs.
The generic ingredient in DIFLUNISAL is diflunisal. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the diflunisal profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Diflunisal
A generic version of DIFLUNISAL was approved as diflunisal by TEVA on July 31st, 1992.
Summary for DIFLUNISAL
US Patents: | 0 |
Applicants: | 7 |
NDAs: | 9 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 120 |
Clinical Trials: | 6 |
Patent Applications: | 3,272 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for DIFLUNISAL |
DailyMed Link: | DIFLUNISAL at DailyMed |
Recent Clinical Trials for DIFLUNISAL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Bristol-Myers Squibb | Phase 1 |
Federal University of São Paulo | Phase 4 |
Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 |
Pharmacology for DIFLUNISAL
Drug Class | Nonsteroidal Anti-inflammatory Drug |
Mechanism of Action | Cyclooxygenase Inhibitors |